07:00 , Jun 11, 2015 |  BC Innovations  |  Translation in Brief

Drop everything

Two groups at Harvard University have independently developed large-scale methods for analyzing gene expression characteristics of cells at a single-cell level, feeding a growing interest in cell biology for combining micro-scale detail with macro-scale throughput. "Clearly...
07:00 , Apr 24, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine/metabolic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Obesity Ubiquitin D (UBD; FAT10) Mouse studies suggest inhibiting FAT10 could help treat obesity. In mice,...
07:00 , Jul 22, 2013 |  BC Week In Review  |  Company News

Allon, Paladin deal

Paladin completed its acquisition of neurology company Allon for C$1 ($0.96) for all outstanding Allon shares, plus C$900,000 ($866,637) in cash. Paladin said Allon will be a Paladin subsidiary for a short period and then...
07:00 , Jun 17, 2013 |  BC Week In Review  |  Company News

Allon neurology news

Allon Therapeutics Inc. (TSX:NPC), Vancouver, B.C.   Business: Neurology   Allon said its trustee Deloitte & Touche Inc. received an unsolicited offer from an undisclosed third party to acquire Allon. Allon said Deloitte is investigating the matter...
07:00 , Jun 10, 2013 |  BC Week In Review  |  Company News

Allon, Paladin neurology news

Paladin proposed to purchase all issued and outstanding Allon shares for C$1 total, plus C$900,000 ($867,807) in cash. Allon believes that its creditors "will derive a greater benefit as a result" of the proposed acquisition...
08:00 , Jan 7, 2013 |  BioCentury  |  Finance

4Q Stock Wrap-Up: Go big or go home

Large cap biotechs were the only market cap segment to end 4Q12 in the black, finishing up 1% to post a 26% gain on the year. Small caps brought up the rear in 4Q, but...
08:00 , Dec 24, 2012 |  BC Week In Review  |  Clinical News

Davunetide: Phase II/III data

Allon said it will not allocate any additional capital to R&D for davunetide after top-line data from a double-blind, international Phase II/III trial in 313 patients with PSP showed that twice-daily 30 mg davunetide administered...
08:00 , Dec 24, 2012 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Alexza Pharmaceuticals Inc. (NASDAQ:ALXA) was off $0.43 to $5.79 on Friday after FDA approved an NDA for Adasuve Staccato loxapine to treat acute agitation in adults with schizophrenia or bipolar disorder with a boxed...
02:15 , Dec 19, 2012 |  BC Extra  |  Clinical News

Allon plummets on davunetide update

Allon Therapeutics Inc. (TSX:NPC) fell C$0.41 (94%) to C$0.03 on Tuesday after the company said it will not allocate any additional capital to R&D for davunetide and will take immediate action to reduce its operating...
08:00 , Dec 3, 2012 |  BC Week In Review  |  Financial News

Allon financial update

Allon filed a shelf registration covering the sale of up to C$50 million ($50.3 million) of its securities. The company, which closed Friday at C$0.50, has 140.8 million shares outstanding. Allon Therapeutics Inc. (TSX: NPC),...